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Background: Studies investigating the association between antipsychotic use and the risk of cerebro-
vascular accident (CVA) showed inconsistent results.
Aim: Conduct a systematic review and meta-analysis to evaluate whether use of antipsychotics is
associated with increased risk of CVA.
Methods: Major electronic databases were searched from 1970 to October 2016 for observational studies
investigating the risk of CVA among users of antipsychotics. Pooled estimates of odds ratios (ORs) and
95% conﬁdence intervals (CIs) were obtained by random effects meta-analysis.
Results: Of 1171 citations identiﬁed, 10 studies were considered eligible. Signiﬁcant increase in risk of CVA
was associated with ﬁrst-generation antipsychotics (OR 1.49; 95% CI 1.24e1.77) but not with second-
generation antipsychotics (OR 1.31; 95% CI 0.74e2.30). Use of any antipsychotics in patients with de-
mentia was associated with a low risk of CVA (OR 1.17; 95% CI 1.08e1.26).
Conclusions: The available evidence suggests use of with ﬁrst-generation antipsychotics as opposed to
second-generation antipsychotics signiﬁcantly increased the risk of CVA.
 2017 AMDA e The Society for Post-Acute and Long-Term Care Medicine.Use of antipsychotics among the public continues to rise around
the world.1e5 Increases in national antipsychotic utilization were seen
in the United States from 1995 to 2008 and in England from 1998 to
2010.1,4 Throughout much of the world, the prescribing indication for
antipsychotics is principally for schizophrenia, but these medications
are commonly prescribed for a broad range of diseases other thanTaiwan National Ministry of
02 -039 -MY3. No funding
nd analysis, decision to pub-
, ScD, Health Economics and
y Medicine, National Taiwan
eng District, Taipei City 100,
te and Long-Term Care Medicine.schizophrenia. Such diseases include psychotic and affective disor-
ders, personality and anxiety disorders, and agitation in dementia.5,6
The rise in the use of antipsychotics is alarming as several life-
threatening adverse effects have been reported with their use.
Studies have linked the use of antipsychotic medications to
adverse metabolic events, adverse cardiovascular events, and even
death.6e13 In addition, the use of antipsychotics has been associated
with an increased risk of cerebrovascular accidents (CVAs) in a
number of studies and systematic reviews; however, with conﬂicting
evidence in the literature, this association remains controversial.14,15
Until recently, the positive correlation between antipsychotic use
and risk of CVAwas primarily seen in elderly adults, particularly those
with dementia.16e19 It is unclear whether use of antipsychotics in the
general population is also associated with increased risk of cerebro-
vascular events. In addition, the risk of CVA reported in the literature
varies considerably depending on the type of antipsychotic used. A
W.-T. Hsu et al. / JAMDA xxx (2017) 1e82number of studies have shown a higher risk of CVA associated with
typical or ﬁrst-generation antipsychotics (FGAs) compared with
atypical or second-generation antipsychotics (SGAs),6,16,20 others have
suggesting the opposite,21,22 and some studies have even indicated no
difference between the 2 classes.23e25 Despite the controversy in the
available evidence, the US Food and Drug Administration issued a
boxed warning on the increased risk of death and cerebrovascular
events when FGAs are used for the off-label indication of dementia.26
Given the contradicting nature of the evidence, we conducted a
systematic review and meta-analysis to determine whether use of
antipsychotics is associated with an increased risk of CVA.1171 citations identified from 
literature search, 460 from MEDLINE 
and 711 from EMBASE database
1037 citations excluded based on screening 
of titles and abstracts using pre defined 
criteria
23 potentially relevant articles 
111 citations excluded because of overlapMethods
Search Strategy
We performed this study in accordance with the Meta-analysis of
Observational Studies in Epidemiology (MOOSE) guidelines. Ethical
Committee approval was not required for the meta-analysis. We
searched PubMed and EMBASE for published studies from 1970 to
October 2016 that explored the risk of CVA associated with use of
antipsychotic medications. The search terms included “antipsychotic,”
“anti psychotic,” “antipsychotic drugs,” “Chlorpromazine,” “Haloper-
idol,” “Bromperidol,” “Fluphenazine,” “Zuclopenthixol,” “Pentixol,”
“Flupentixol,” “Levopromazine,” “Perphenazine,” “Pimozide,” “Pen-
ﬂuridol,” “Sulpiride,” “Amisulpride,” “Amoxapine,” “Asenapine,” “Ari-
piprazole,” “Blonanserine,” “Clozapine,” “Iloperidone,” “Melperone,”
“Olanzapine,” “Risperidone,” “Paliperidone,” “Quetiapine,” “Sertindole,”
“Lurasidone,” “Ziprasidone,” “cerebrovascular accidents,” “cerebrovas-
cular disorders,” “ischemic stroke,” “hemorrhagic stroke,” “transient
ischemic attack,” and “stroke.” Antipsychotics include FGAs and SGAs
based on the US Food and Drug Administration drug classiﬁcation.27e29
We used “cerebrovascular disorders,” “ischemic stroke,” “transient
ischemic attack,” “TIA,” “hemorrhagic stroke,” “stroke,” and “brain
infarction” as the search terms for the outcomes of interests. We did not
set restrictions on geography or language, and we did not seek
unpublished investigations. Two investigators (W. H., C. L.) indepen-
dently examined all titles and abstracts and obtained full texts of
potentially relevant articles. Following the database search, a review of
the abstracts was conducted to rule out the studies that involved case
reports, case series, reviews, editorials, clinical trials, systematic
reviews, meta-analyses, or clinical guidelines. To be eligible for inclu-
sion, studies must have met the following criteria: (1) observational
study with a control group, (2) nonuse of any antipsychotic served as a
reference group, (3) reported data on CVA outcomes, and (4) offered
sufﬁcient data to construct risk estimates. The same cohort reported in
different articles was evaluated to include the most recent publication.
Publications by the same author or group of authors were also carefully
investigated to exclude overlapping cohorts or results. The most recent
study results were included for further meta-analysis. We abstracted
data from full-text articles using structured review forms, and
disagreements were resolved by consensus meetings.identified for further review
13 citations excluded after full-text review
2 letters to the editor
5 outcome of interest not studied or 
reported
1 exposure was defined as
antidepressants
5 non antipsychotic users not compared
10 articles included in meta-analysis
Fig. 1. PRISMA ﬂow-diagram for selection of articles for meta-analysis.Data Extraction and Quality Assessment
For all studies, we extracted information on the ﬁrst author’s sur-
name, year of publication, country, study design, sources of database,
sociodemographics, sample sizes, case numbers, duration of study,
exposure, outcomes of interests, crude and adjusted effect sizes as
available, and matching and confounding factors. We used the
Newcastle-Ottawa Scale (NOS) to assess the quality of included
studies.30 Studies awarded more than 6 stars were considered high
quality, and 9 stars represented the highest quality.Data Synthesis
Our primary measure of interest was the pooled odds ratio (OR) of
CVA related to the exposure of any antipsychotics. Secondary measures
of interest were exposure to FGAs or SGAs compared with nonusers.
Subgroup analyses were conducted for the following subgroups: elderly
population, population with dementia, case-control study design, and
population-based study design. Pooled ORs were estimated by the
Mantel-Haenszelmethod.31 Publication biaswas assessed using the Begg
adjusted rank correlation test and the Egger regression asymmetry test.
The Begg adjusted rank correlation test was used to measure the cor-
relation between estimates of treatment effect and variances. Similarly,
the Egger asymmetry test is a regression of the standardized treatment
effects on the standard errors. For both methods, a signiﬁcant result
suggests correlation between effect size and estimates of precisionwhich
would be evidence of publication bias. Visual assessment was conducted
by constructing funnel plots. A funnel plot is a scatter plot of the effect
measure estimate on the horizontal axis vs the standard error of the
effect estimate on the vertical axis. The plot should form a pyramid in the
absence of bias.32,33 To assess consistency and evaluate heterogeneity, we
calculated the I2 statistic. A ﬁxed-effect model was used for I2 less than
50%, whereas random-effects model was used for studies with I2 greater
than 50%.34,35 All meta-analyses were performed using Stata statistical
software v 12 (StataCorp, College Station, TX).
Results
Study Selection and Characteristics
The number of articles excluded and the reasons for exclusion of
each individual article are reported in the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) ﬂow diagram
(Figure 1). Our search strategy yielded 1171 references, 23 of which
were considered eligible for full-text review. Of these, we excluded 9
studies for the reasons reported in the Figure 1. Finally, 10 articles met
the inclusion criteria andwere included in themeta-analysis. These 10
studies16,19,25,36e42 included 16,993 CVA cases from 5 case-control
studies,16,19,36e38 1 case-case-time-control,40 1 self-control case
series study,411 cross-sectional study,25 and 2 cohort studies.39,42 Nine
of the studies identiﬁed patients from administrative
W.-T. Hsu et al. / JAMDA xxx (2017) 1e8 3databases,16,19,36e42 whereas 1 study used an electronic health record
(Table 1).25 All studies included adult participants, 8 of which focused
on elderly patients,16,19,36e39,41,42 and 5 of which included patients
with dementia.16,19,38,41,42 Characteristics of individual studies are
summarized in Table 1.
Study Quality
Quality evaluation by the NOS is summarized in Table 2. All
included studies used appropriate design. The studies varied with
respect to their exposure and case deﬁnitions. Current use of FGAs or
SGAs was the most frequent measure of exposure, whereas other
studies further classiﬁed drug use into recent or past users, high-dose
or low-dose users, and short-term or long-term users. All 10 included
studies used the deﬁnition of CVA provided by the International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation or Inter-
national Classiﬁcation of Diseases, Tenth Revision, Clinical Modiﬁcation
as their main outcome. Only 1 study performed CVA diagnosis
validation from reviewed medical records.42 The studies also varied inTable 1
Characteristics of Included Studies
Authors
(Location, Year)
Setting and Study Population Sample Size Exposure
Liperoti et al38
(USA, 2005)
SAGE database, age older
than 65 years
4788
(case 1130)
FGAs and SGAs
Douglas et al41
(UK, 2008)
UK-based General practice
research database
6790 FGAs and SGAs
Sacchetti E et al39
(Italy, 2008)
HSD, age older than 65 years 74,162
(case 2507)
FGAs and SGAs
except aripipr
and ziprasido
Kleijer et al36
(The Netherlands,
2009)
PHARMO (The PHARMCO Institute,
Utrecht, The Netherlands),
PRISMANT (previously known as
the Dutch Centre for Healthcare
Information [LMR database])
database, age older than 50 years
26,157
(case 518)
FGAs and SGAs,
current, recen
past and past
Chan et al42
(Hong Kong,
2010)
Hospital-based database, age
older than 65 years
1089
(case 107)
FGAs and SGAs
Laredo et al16
(UK, 2011)
UK-based General Practice
Research Database, age older
than 65 years
18,762
(case 3149)
FGAs and SGAs
Wang et al40
(USA, 2012)
Veterans Health Administration
Database
14,671
(case 511)
FGAs and SGAs
Hsieh et al37
(Taiwan, 2013)
National Health Insurance
Research Database of Taiwan
9715
(case 386)
FGAs and SGAs,
current, recen
past use
Liu et al19
(Taiwan, 2013)
National Health Insurance
Research Database, aged
older than 65 years
2243
(case 811)
FGAs and SGAs
Mundet-Tudurí
et al25
(Spain, 2013)
Electronic health record from
51 primary care centers in
Barcelona, aged between
18 and 95 years old
27,811
(case 1084)
FGAs and SGAs
BMI, body mass index; HDL, high-density lipoprotein; ICD-9-CM, International Classiﬁ
Statistical Classiﬁcation of Diseases and Related Health Problems, 10th Revision, Clinical M
Database; SAGE, Systematic assessment of geriatric drug use via epidemiology.the adjusted covariates. All studies comprehensively adjusted for
potential confounders in their analysis. In terms of overall quality, 5
studies received 9 stars and 4 studies received 8 stars when evaluated
using NOS, indicating low risk of bias (Table 2).
Antipsychotics and Risk of CVA
Nine out of 10 studies examined the pooled use of both FGAs and
SGAs (Table 3). Combining FGAs and SGAs, use of any antipsychotics
was associated with an increased risk of CVA [OR 1.45; 95% conﬁdence
interval (CI) 1.24e1.70; I2 ¼ 91.0%]16,19,25,36e38,40e42 (Figure 2A).
Restricting the analysis to only population-based studies, use of any
antipsychotics was still associated with an increased CVA risk (OR
1.51; 95% CI 1.20e1.91; I2 ¼ 93.3%).16,19,25,36,37,40 Seven studies inves-
tigated the use of any antipsychotics in the elderly population, and a
similar increase in CVA risk was observed (OR 1.49; 95% CI 1.25e1.77;
I2 ¼ 89.1%).16,19,36e38,41,42 However, only 4 studies evaluated the use of
any antipsychotics in dementia patients and the results showed a low
risk of CVA (OR 1.17; 95% CI 1.08e1.26; I2 ¼ 0%).16,19,38,42 Five studiesOutcome Deﬁnition and
Case Ascertainment
Adjustment in Multivariate
Analysis
Hospital claim for ischemic stroke
and transient ischemic attack
identiﬁed by ICD-9-CM
Comorbidity, age, sex, ethnicity,
concomitant medications, body
mass index, activities of daily living
scale score, Cognitive Performance
Scale score, behavior index score
Diagnosis of stroke in the database
identiﬁed by ICD-10-CM
Self-control case series
azole
ne
Hospital claim for stroke identiﬁed
by ICD-9-CM; stroke, hemiparesis
or hemiplegia registered in the
HSD during the follow-up
Comorbidity, chronic disease score,
age, sex, indication of use for an
antipsychotic, use of drugs during
follow-up
t
use
Hospital claim for ischemic or
hemorrhagic stroke identiﬁed by
ICD-9-CM
Comorbidity, medications, age, sex,
type of antipsychotics (high- or
low-central a1-adrenoreceptor
afﬁnity, high- or low-central
a1-adrenoreceptor afﬁnity)
Cerebrovascular adverse events
validated by medical records
Comorbidity, age, sex, medications
(benzodiazepine, antidepressants)
Hospital claim for cerebrovascular
accident identiﬁed by ICD-9-CM
Sociodemographics (age, sex),
myocardial infarction, mitral
stenosis, atrial ﬁbrillation, heart
failure, diabetes mellitus,
hyperlipidemia, hypertension,
obesity, anticoagulants, platelet
inhibitors, lipid-lowering drugs,
oral hypoglycemic agents, insulin,
and antihypertensive drugs
Ischemic stroke identiﬁed by
ICD-9-CM, validated by Reker
et al’s high speciﬁcity stroke
diagnostic code algorithm
Unmeasured time-invariant
confounders, exposure-time trends,
medications
t and
Hemorrhagic stroke, ischemic
stroke, or transient ischemic
attack identiﬁed by ICD-9-CM
Comorbidity, medications
Hospital claim for stroke identiﬁed
by ICD-9-CM
Age, sex, monthly income,
geographic region, hypertension,
diabetes
Diagnosis of stroke in the database
identiﬁed by ICD-10-CM
Sociodemographics (age, sex), clinical
characteristics (comorbidity,
co-medications), smoking, BMI,
blood pressure, blood sugar, HDL
cholesterol, LDL cholesterol,
triglycerides
cation of Diseases, Ninth Revision, Clinical Modiﬁcation; ICD-10-CM, International
odiﬁcation; LDL, low-density lipoprotein; UK, United Kingdom; HSD, Health Search
Table 2
Quality Assessment of Included Studies Based on the NOS
Authors
(Location, Year)
Selection (Design) Comparability Exposure Outcome Total NOS Stars
Liperoti et al38
(USA, 2005)
+++ ++ +++ 8 High quality study
Sacchetti et al39
(Italy, 2008)
+++ ++ +++ 8 High quality study
Kleijer et al36
(The Netherlands 2009)
++++ ++ +++ 9 High quality study
Chan et al42
(Hong Kong, 2010)
++++ ++ +++ 9 High quality study
Laredoet al16
(UK, 2011)
++++ ++ +++ 9 High quality study
Wang et al40
(USA, 2012)
++++ ++ +++ 9 High quality study
Hsieh PH et al37
(Taiwan, 2013)
+++ ++ +++ 8 High quality study
Liu et al19
(Taiwan, 2013)
++++ ++ +++ 9 High quality study
W.-T. Hsu et al. / JAMDA xxx (2017) 1e84used case-control design and the remaining studies used other
designs.16,19,36e38 Restricting analysis to case-control studies showed
an attenuated but signiﬁcant risk of CVA with antipsychotic use (OR
1.28; 95% CI 1.12e1.47; I2 ¼ 59.0%).
In addition, studies were evaluated to determine whether CVA risk
differs between FGAs and SGAs (Figure 2B and C). Use of FGAs was
associated with a signiﬁcant increase in risk of CVA (OR 1.48; 95% CI
1.24e1.77; I2 ¼ 85.2%), but use of SGAs had an attenuated and
nonsigniﬁcant risk of CVA (OR 1.31; 95% CI 0.74e2.30; I2 ¼ 94.8%).
Excluding studies that used hospital patients as their control showed
an increased risk of CVA with FGAs (OR 1.95; 95% CI 1.12e3.37;
I2 ¼ 38.2%)16,36,37 but not with SGAs (OR 1.15; 95% CI 0.46e2.87;
I2 ¼ 97.6%).16,37,39 The subgroup analyses that evaluated all studies
without dementia patients showed increased risk of CVA for both
FGAs (OR 1.97; 95% CI 1.42e2.73; I2¼ 38.2%) and SGAs (OR 1.69; 95% CI
0.79e3.63; I2 ¼ 97.8%).25,36,37,39e41
Publication Bias
The test for publication bias did not yield signiﬁcant results in 3
main medication categories. The results of the Egger test indicated no
evidence of publication bias in both FGA and SGA users (P ¼ .72),
which was consistent with the Begg test (P ¼ .76). Among FGA users,
no signiﬁcant evidence of potential publication bias was noted using
the Begg test (P ¼ .46) and Egger test (P ¼ .63). The Begg test of SGAs
suggested no signiﬁcant evidence of potential publication bias
(P¼ 1.00) (Table 4). Funnel plots of the 3 main exposure categories areTable 3
Summary of Subgroup Analysis
Categories Number
Studies
Exposure to overall antipsychotics
All studies 9
Elderly population 7
Dementia population 4
Population-based study 6
Case-control design 5
Exposure to FGAs
All studies 6
Exclusion of studies using hospital controls 3
Exclusion of studies using dementia population 3
Exposure to SGAs
All studies 6
Exclusion of studies using hospital controls 3
Exclusion of studies using dementia population 3shown in Figure 3. These plots present no clear asymmetry and
support the results of the aforementioned tests.
Discussion
We reviewed the literature and quantitatively summarized the
existing observational studies that evaluated the association between
antipsychotic use and CVA risk. A total of 186,188 antipsychotic users
and roughly 17,000 CVA cases were identiﬁed, which is by far the
largest systematic review conducted to date. Our meta-analysis
showed that use of antipsychotics increases CVA risk, regardless of
patient age or study design. Compared with nonusers, users of
antipsychotic medications have an approximately 1.5-fold increased
risk of developing CVA. Heterogeneity of strengths of association may
reﬂect true pharmacologic differences in type of antipsychotics,
differences in study methodology, and the distribution of effect
modiﬁers such as patient age or presence of dementia. Greater risk
was seen among the elderly population, whereas risk of CVA in
dementia patients was not as pronounced. In the subgroup analysis,
FGAs and SGAs showed differences in CVA risk. Use of FGAs was
associated with a nearly 1.5-fold increased risk of CVA, whereas use of
SGAs was associated with an attenuated (1.3-fold) and nonsigniﬁcant
increase in CVA risk.
Our overall ﬁndings are consistent with the results reported in 2
previous systematic reviews, which suggest antipsychotics may
trigger cerebrovascular events.43,44 The review by Sacchetti et al43
included both randomized clinical trials and observational studies,of Summary Estimate
(95% CI)
I2
1.45 (1.24e1.70) 91.0%
1.49 (1.25e1.77) 89.1%
1.17 (1.08e1.26) 0%
1.51 (1.20e1.91) 93.3%
1.28 (1.12e1.47) 59.0%
1.48 (1.24e1.77) 85.2%
1.95 (1.12e3.37) 72.9%
1.97 (1.42e2.73) 38.2%
1.31 (0.74e2.30) 94.8%
1.15 (0.46e2.87) 97.6%
1.69 (0.79e3.63) 97.8%
Fig. 2. Forest plot of risk of CVA-associated with (A) any antipsychotics, (B) FGAs, and (C) SGA.
W.-T. Hsu et al. / JAMDA xxx (2017) 1e8 5while the Pratt et al44 review evaluated only observational studies.
Neither review, however, performed meta-analyses to provide
summary estimates. The review by Sacchetti et al showed that
incidence of CVA was consistently increased in the antipsychotic
arm, but the small sample size of each trial prevented a conclusive
outcome. The Pratt et al review was also descriptive but noted that
the results may have been greatly inﬂuenced by the study design.44Moreover, the 2 reviews suggested a low risk of CVA associated
with antipsychotic use among people with dementia, but a high
CVA risk associated with antipsychotic use in the elderly
population. Unlike the aforementioned reviews, our updated
review computed pooled summary estimates across different
subgroups, determined sources of heterogeneity, and included 5
additional eligible studies. Our quantitative analysis conﬁrmed the
Fig. 2. (continued).
W.-T. Hsu et al. / JAMDA xxx (2017) 1e86observation that elderly users of antipsychotics had a moderate
risk of CVA but users with dementia did not have a low risk of CVA
as previously observed. All but 4 studies used case-control design
so a subgroup analysis could not be performed for other study
designs. Some studies used hospital patients as their control,
which could attenuate the risk of CVA.
The large number of antipsychotic users is a main strength of this
study, allowing for analysis of CVA risk differences between FGA users
and SGA users. Users of FGAs were found to have a 1.5-fold greater risk
of CVA when compared with nonusers. In contrast to ﬁndings of
previous meta-analyses, this study shows a nonsigniﬁcant association
between use of SGAs and risk of CVA (OR 1.31; 95% CI 0.74e2.30;
I2 ¼ 94.8%). It should be noted that the CI is wide and the measure for
statistical heterogeneity (I2) is high. Two of the eligible studies
reported an increased CVA risk among SGA users,39,41 whereas 4
studies reported no increased risk.16,37,38,42 The heterogeneity in the
observed risk of CVA can be partly attributed to differences in study
design. For study design, 5 studies were case-control,16,19,36e38 1 case-
case-time-control study,40 1 self-control case series study,41 1 cross-
sectional study,25 and 2 cohort studies.39,42 Heterogeneity in CVA
risk may also be attributed to differences in patient selection as
demonstrated in Table 1. Five studies evaluated elderly dementia
patients,16,19,38,41,42 1 study evaluated schizophrenia patients,37 and 6
studies evaluated general or hospitalized elderly patients.25,36e40 Use
of SGAs in patients without dementia resulted in an increased risk of
CVA (OR 1.69, 95% CI 0.79e3.63), but the results remained nonsig-
niﬁcant and heterogeneous. To conﬁrm the potential risk of CVA withTable 4
Tests for Publication Bias
Exposure Begg
P Value
Egger
P Value
Overall .76 .72
FGAs .46 .63
SGAs 1.00 .63SGAs, more high quality population-based observational studies are
required that employ appropriate study designs.
A few meta-analyses have examined the association between
antipsychotics and cerebrovascular events in the population with
dementia. However, the prevalence of dementia is rather low in the
general population, ranging from 38 to 421 per 100,000 persons.45
Given the low prevalence of dementia, it is important to determine
whether the risk of CVA differs among general users of antipsychotics
compared with the population with dementia. To the best of our
knowledge, this is the ﬁrst meta-analysis to investigate the association
between use of any antipsychotics and the risk of CVA in population-
based studies. Our results suggest a high risk of CVA (51%) in general
users of antipsychotics and a low risk of CVA (17%) in dementia
patients.
Although we have performed a very thorough literature review
and meta-analysis, our research is not without limitations. First,
included studies were heterogeneous in terms of study design, timing
of antipsychotic exposure, and diagnostic outcomes. In addition,
despite the fact that the majority of studies were adjusted for many
confounders with high quality results of NOS assessment, we cannot
exclude the possibility of residual confounding for observational
studies, especially being that the effect estimates differed greatly
between a self-control case series design and traditional case control
or cohort designs. Finally, this meta-analysis was limited in its ability
to substantiate potential mechanisms linking antipsychotic use and
risk of CVA, such as direct vascular toxicity, coagulation dysfunction,
or weight gain.
To conclude, our study suggests that overall antipsychotic
exposure is associated with an increased risk of CVA. In addition,
subgroup analysis suggests that elderly patients have a higher risk of
CVA than the population with dementia. Antipsychotic treatments
should still be prescribed based on elderly patients’ individual
beneﬁts and risks especially for behavioral and psychological
symptoms of dementia. These associations may be causal but the
possibility of residual confounding cannot be excluded. It is unlikely
that more detailed information on a large population of
Fig. 3. Funnel plot of effect estimate of CVA risk in users of (A) any antipsychotics, (B) FGAs, and (C) SGAs relative to nonusers. The studies were plotted with the estimated effect on the
horizontal axis and the reciprocal of standard error of the estimated effect on the vertical axis (ie, a measure of precision). Studies with less estimated precision scatter more widely at
the bottom of the graph, whereas studies with more precision should scatter less at the top. The shapes produced do not contradict the results of the Begg and Egger tests.
W.-T. Hsu et al. / JAMDA xxx (2017) 1e8 7antipsychotic users will become available in the immediate future.
Clinicians should be aware of the higher risk of CVA among patients
using antipsychotics, particularly in FGA users and the elderly
population.
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